The Emirates Drug Establishment made the UAE the third country to approve orforglipron for diabetes. Price, coverage and prescriber behaviour are still open, and that is where launch teams should look.
The Emirates Drug Establishment (EDE), the UAE's federal medicines regulator, has approved Eli Lilly's Foundayo (orforglipron) for adults with type 2 diabetes, and says that makes the UAE the third country in the world to clear the pill for that use. The decision was reported by the state news agency WAM on 6 November 2026.
Foundayo is a GLP-1 receptor agonist, the same drug class as Ozempic and Mounjaro. GLP-1 stands for glucagon-like peptide-1, a gut hormone that lowers blood sugar after meals and reduces appetite. Most medicines in the class are injected. Foundayo is a small, non-peptide molecule taken as a tablet once a day, and the regulator stresses that it can be taken without food or water restrictions.
This is the second UAE approval for the drug. The EDE first approved Foundayo for chronic weight management on 3 April 2026, two days after the US Food and Drug Administration (FDA), making the UAE the second country in the world to register it. The new decision adds diabetes to the label. What the announcement did not include is just as important: no price for the diabetes use, no statement on insurance coverage, and no launch date for the new indication.
What exactly was approved
The WAM report, issued from Dubai, says the EDE "approved a new therapeutic indication for Foundayo (orforglipron), developed by Eli Lilly, for the treatment of adults with type 2 diabetes, making the UAE the world's third country to approve the medicine for this use."
The regulator describes the drug as helping to "improve blood glucose control in adults with type 2 diabetes while supporting long-term weight management, as part of a physician-supervised treatment plan that includes an appropriate diet and physical activity."
The rest of the statement is about the system rather than the product. The EDE says the approval fits its goal of a "proactive pharmaceutical regulatory system", aims to widen access to "high-value innovative treatments", and urges residents to understand diabetes risk factors, get screened and keep up with follow-up visits.
The EDE did not say which two countries came first. From public records I could find two. Mexico's regulator, COFEPRIS, authorised the drug under the brand name Foundayz for both obesity and type 2 diabetes on 20 July 2026, according to Mexican press reports. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) authorised orforglipron for weight management and for glycaemic control in type 2 diabetes on 10 August 2026. That would make the UAE third, consistent with the EDE's claim. I could not rule out other approvals that were not publicised, so treat the ranking as the regulator's claim, supported but not proven by the public record.
The US has not yet approved it for diabetes
One point surprises people. In the United States, Foundayo is approved only for weight management. The FDA approved it on 1 April 2026 for adults with obesity, or overweight with at least one weight-related condition. The FDA said the decision came 50 days after filing and was the first new molecular entity cleared under its Commissioner's National Priority Voucher pilot.
Lilly said in April and again in June 2026 that it would file Foundayo for type 2 diabetes with the FDA by the end of the second quarter. As of 10 November 2026 I found no FDA decision on that filing. So for the diabetes indication, the UAE sits ahead of the drug's home market. That is unusual, and it matters for launch planning: there is no US diabetes label or US diabetes price to use as an anchor.
The evidence behind the diabetes label
Lilly built the diabetes case on its ACHIEVE programme, five Phase 3 trials that enrolled more than 6,000 people with type 2 diabetes. The headline results, all from Lilly's own releases and the linked journal publications:
- ACHIEVE-1 (published in the New England Journal of Medicine, June 2025). 559 adults with early type 2 diabetes on diet and exercise alone. At 40 weeks, A1C (a three-month measure of average blood sugar) fell by 1.3% to 1.6% from a baseline of 8.0%, versus 0.1% with placebo. The highest dose produced 7.9% weight loss.
- ACHIEVE-2. 962 adults on metformin. Foundayo lowered A1C by up to 1.7% versus 0.8% with dapagliflozin, a widely used SGLT2 inhibitor tablet, at 40 weeks.
- ACHIEVE-3. 1,698 adults on metformin, and the first head-to-head Phase 3 trial of two oral GLP-1 drugs. At 52 weeks, Foundayo 17.2 mg lowered A1C by 2.2% versus 1.4% with oral semaglutide 14 mg, and cut weight by 9.2% versus 5.3%.
- ACHIEVE-4. More than 2,700 adults with type 2 diabetes and overweight or obesity at raised cardiovascular risk, compared with insulin glargine. Foundayo met its primary goal of non-inferiority on major cardiovascular events (hazard ratio 0.84). Lilly also reported 57% lower all-cause death in a pre-planned analysis, but that analysis was not controlled for multiplicity, so it is a signal, not proof.
- ACHIEVE-5. 546 adults already on insulin glargine. Foundayo lowered A1C by up to 2.1% versus 0.8% with placebo.
Two cautions belong next to these numbers. First, side effects. The most common adverse events were gastrointestinal: nausea, diarrhoea, vomiting and indigestion. In ACHIEVE-3, 9.7% of people on the top dose of Foundayo stopped because of side effects, against 4.9% on the top dose of oral semaglutide. In ACHIEVE-2 the top-dose figure was 12.4% versus 1.2% with dapagliflozin. Tolerability, not efficacy, may decide how many patients stay on the drug.
Second, the trials used an investigational capsule in some studies, with doses (3 mg, 12 mg, 36 mg) that differ from the marketed tablet strengths (0.8 mg to 17.2 mg). Lilly says the doses are equivalent. Anyone comparing figures across sources should check which formulation is being quoted.
Why a diabetes label matters more than it sounds
The molecule did not change on 6 November. What changed is who can be treated on label, and that has three practical consequences.
It opens the larger patient pool. The International Diabetes Federation's Diabetes Atlas (11th edition, 2025) estimates 1.27 million adults aged 20 to 79 with diabetes in the UAE in 2024, an adult prevalence of 16.5% (20.7% age-adjusted). Across the Middle East and North Africa region, IDF counts 84.7 million adults with diabetes in 2024, projected to rise 92% to 162.6 million by 2050. Most of these people have type 2 diabetes. A prevalence figure is not a treated, eligible or paid-for population, but it shows why the diabetes indication carries more commercial weight than the obesity one alone.
It changes the comparators. In obesity, Foundayo competes mostly with other weight-loss medicines. In diabetes it enters a crowded treatment pathway: metformin, SGLT2 inhibitors, DPP-4 inhibitors, insulin, injectable GLP-1 drugs and oral semaglutide. Each prescribing decision is now a comparison against an established habit, and ACHIEVE-2 and ACHIEVE-3 were designed with exactly those comparisons in mind.
It may change who pays. This is the point I would watch most closely. In many health systems, diabetes medicines are covered more routinely than weight-loss medicines. Whether that holds for Foundayo in the UAE is not public. The EDE statement says nothing about price, formulary listing or insurer coverage for the diabetes indication. Until those details appear, the approval is a licence to sell, not proof of access.
What the UAE has already shown with the obesity launch
The obesity launch gives some clues about how fast the UAE moves once a drug is approved.
The EDE approval on 3 April 2026 said the drug was expected to reach eligible patients from May 2026. On 24 April, the Department of Health Abu Dhabi said it had added the pill to its Personalised Weight Management Programme with the Abu Dhabi Public Health Centre, delivered through Imperial College London Diabetes and Endocrine Centre, and that the treatment "will be covered for eligible adults under the programme." That is coverage within a defined programme in one emirate, not a federal reimbursement decision, but it shows that public payers in Abu Dhabi were willing to act within weeks.
The commercial signal is visible too. Lilly reported Foundayo revenue of $184 million in the third quarter of 2026 and $281 million for the first nine months of the year. Lilly does not break that figure down by country. Pharmaphorum reported in August that the UAE was one of only two markets where the drug was commercially available at that point, and that analysts saw a solid UAE contribution in the second quarter. I could not confirm a UAE revenue number, and none should be assumed.
There is a supply angle as well. On 20 October 2026, the Abu Dhabi Media Office announced a collaboration between Mubadala Bio and Lilly on localised packaging and logistics of Lilly's GLP-1 medicines from a 125,000 square metre site in KEZAD, Abu Dhabi, to be introduced in phases. The signing was witnessed by EDE Director General Dr Fatima Al Kaabi and by Tayllit Aherdan, Lilly's Vice President and General Manager for the Gulf (UAE, Kuwait and Qatar). The release does not say which products will be packed first, or when.
What is still not known
Before anyone builds a forecast, it is worth listing what the public record does not say:
- Price. No UAE price for Foundayo in diabetes has been published. Our earlier analysis of UAE drug pricing after the EDE takeover explains why a filed price, a published price and a reimbursed price are three different things.
- Coverage. No statement from the Department of Health Abu Dhabi, the Dubai Health Authority or major insurers on covering the diabetes indication.
- Launch timing. No date for when the diabetes indication will be promoted or stocked under the new label.
- Label detail. The EDE did not publish the full UAE indication wording, for example whether use is restricted to second line after metformin.
- The FDA decision. Still pending as far as I could find. A US diabetes label, or a delay, would shape global positioning.
- The rest of the Gulf. The Saudi Food and Drug Authority approved Foundayo for weight management on 2 August 2026. I found no public Saudi approval for type 2 diabetes yet.
The research questions that matter now
In my view, the regulatory story is mostly told. The commercial story is not. For teams working on diabetes, obesity or GLP-1 products in the UAE and wider GCC, whether at Lilly, a competitor or a payer, these are the questions I would want answered with evidence rather than assumptions.
1. Where will physicians place an oral GLP-1 in the diabetes pathway? Endocrinologists, internists and family physicians may see Foundayo as an early add-on to metformin, as an alternative for patients who refuse injections, or as a step before insulin. Each position implies a very different patient volume. Structured physician interviews and a quantitative survey can show where it is likely to land, and why.
2. How do prescribers weigh efficacy against tolerability? ACHIEVE-3 showed better A1C and weight results than oral semaglutide, but also higher discontinuation from side effects. Physicians will make their own trade-off. Research should test how much the efficacy gap matters to them versus the dropout risk, and which patients they would avoid.
3. Does "no food or water restrictions" change behaviour? The US label for oral semaglutide (Rybelsus) says to take it on an empty stomach with up to 4 ounces of plain water and wait at least 30 minutes before eating. Foundayo does not need that. Patient research can show whether this convenience actually improves adherence in UAE patients, including during Ramadan fasting, when dosing routines change for many people with diabetes.
4. Who pays, and under what rules? The obesity launch in Abu Dhabi ran through a programme with defined eligibility. The diabetes indication may be handled through standard formularies and insurer benefit tables instead. Payer and insurer interviews can map the likely route, prior authorisation rules and the price at which coverage becomes realistic. For context on how recent price changes affect diabetes listings, see our UAE diabetes price-cut research.
5. How will one product with two indications be managed? The same tablet is now approved for weight management and for diabetes. If coverage differs between the two, pharmacists, prescribers and patients will face questions about which use a prescription is for. Pharmacist and physician research can show where confusion or off-label switching is most likely.
6. What does the approval mean for injectable GLP-1 brands? Injectable GLP-1 drugs are well established in UAE diabetes care. Some patients may switch to a pill, while others will stay with a weekly injection. Demand research should size switching intent rather than assume it.
7. How does the UAE connect to the rest of the GCC? The UAE has now been early for both indications. Saudi Arabia has the weight-management approval. Kuwait and Qatar sit under the same Lilly Gulf leadership as the UAE. Launch sequencing, reference pricing and cross-border patient flows are all research topics in their own right. Our Roche and DoH Abu Dhabi diabetes analysis covers how Abu Dhabi structures diabetes partnerships.
Who gains, who loses, and what a sceptic would say
Possible winners. People with type 2 diabetes who want an oral option with strong A1C and weight effects and no dosing restrictions. Lilly, which gains a second use for a drug already selling in the UAE. The EDE, which strengthens its record of early approvals.
Possible losers. Older oral diabetes medicines if physicians move GLP-1 therapy earlier in the pathway. Oral semaglutide, which now faces a head-to-head trial it lost on the primary endpoint. Payers, if demand grows faster than budgets.
The sceptic's case. A sceptic would point out that being "third in the world" is a regulatory milestone, not a patient outcome. They would note that the highest-dose discontinuation rates in ACHIEVE-2 and ACHIEVE-3 were roughly double or more those of the comparators, that the all-cause death finding in ACHIEVE-4 was not controlled for multiplicity, and that without a published price or coverage decision, access is still theoretical. All of these are fair points, and they are precisely the gaps research can fill.
What to watch next
- FDA decision on the diabetes filing. Lilly filed, or planned to file, by the end of June 2026.
- UAE price and coverage. Any EDE pricing decision, Abu Dhabi or Dubai formulary update, or insurer announcement for the diabetes use.
- Saudi Arabia. Whether the SFDA adds a diabetes indication to its August 2026 weight-management approval.
- Mubadala Bio packaging. Which Lilly GLP-1 products are packed first at KEZAD, and when.
- Full ACHIEVE-4 publication. Peer-reviewed detail on cardiovascular and mortality results.
What launch and access teams should do now
- Separate the two indications in every plan. Forecast obesity and diabetes demand on separate rows, with separate payers and eligibility rules.
- Map the pathway position with physicians now, before promotional messages shape opinion.
- Test the price corridor with payers, using the obesity programme in Abu Dhabi as one reference point, not the only one.
- Run patient research on oral versus injectable preference, including Ramadan dosing and adherence.
- Track competitor responses, especially from oral semaglutide and injectable GLP-1 brands, through regular physician and pharmacist panels.
How BioNixus helps
BioNixus has run healthcare market research since 2012, with 118 clients in 48 countries and 127 studies in 2026 so far. Our physician network includes more than 82,000 physicians globally and about 3,200 in the Middle East. We work from our USA office (Americas office and global HQ), our UK office (Europe), our Cairo office (AMEA) and our Dubai field office for the UAE.
For diabetes and GLP-1 teams in the UAE and GCC, we run physician insights studies with endocrinologists, internists and family physicians; patient research on adherence, preference and out-of-pocket spend; and market access research with payers and insurers on pricing and coverage. See our UAE healthcare market research page for local capabilities, and our GLP-1 competition analysis for the global picture.
If you need physician, patient or payer evidence on Foundayo's diabetes positioning before price and coverage decisions are set, contact BioNixus and we can scope the study within 48 hours. Visit bionixus.com to learn more.
